期刊文献+

AFP和高尔基体糖蛋白-73联合检测诊断原发性肝癌临床评价 被引量:4

Combined diagnosis value of Golgi protein 73 and alpha-fetoprotein in primary hepatic cancer
下载PDF
导出
摘要 目的探讨甲胎蛋白(AFP)和高尔基体糖蛋白-73(GP73)在PHC诊断中的指导意义。方法采用电化学发光法分别对64例肝癌组和72例对照组进行血清AFP及GP73的含量检测,分析AFP、GP73及AFP和GP73联合检测时在PHC诊断时的敏感性和特异性。结果 64例PHC癌患者中,57例(89.01%)为肝细胞癌。AFP和GP73在肝癌组患者血清中的含量分别为(318.27±169.32)ng/ml和(262.74±168.98)ng/ml,明显高于对照组血清中的(14.16±8.45)ng/ml和(37.04±20.56)ng/ml,P均<0.01。AFP和GP73联合检测敏感性及特异性可达88.39%和86.36%,与单项检测相比,可明显提高诊断的准确性。结论血清中AFP及GP73是PHC发生、发展的重要检测指标,两者联合检测对肝癌患者诊断及预后具有重要。 Objective To investigate the effect and diagnostic signifi cance of alpha-fetoprotein(AFP) and Golgi protein 73(GP73) in the serum of primary hepatic cancer(PHC) patients. Methods We retrospectively analyze 64 cases of liver cancer and 72 healthy people respectively by electrochemiluminescence determination of serum AFP and GP73. The sensitivity and specifi city of serum AFP, GP73, and AFP + GP73 in the diagnosis of PHC were analyzed. Results The 89.01%(57/64) of PHC patients were HCC patients and AFP + GP73. The serum levels of AFP and GP73 in PHC patients [(318.27 ± 169.32) ng/ml,(262.74 ± 168.98) ng/ml] were signifi cantly higher than in healthy people [(14.16 ± 8.45) ng/ml,(37.04 ± 20.56) ng/ml](P 0.01). The sensitivity and specifi city value of AFP combined with GP73 were 88.39% and 86.36%, respectively. Compared with single detection, AFP and GP73 combined detection had an higher diagnosis accuracy in PHC. Conclusions Serum levels of AFP and GP73 are important factors of PHC occurrence and development indicators. The AFP and GP73 combined detection has important significance for PHC diagnosis and prognosis estimation.
作者 邓广博
出处 《中国肝脏病杂志(电子版)》 CAS 2014年第4期68-70,共3页 Chinese Journal of Liver Diseases:Electronic Version
关键词 肝肿瘤 甲胎蛋白类 高尔基体 糖蛋白类 Liver Neoplasms Alpha-fetoproteins Golgi apparatus Glycoproteins
  • 相关文献

参考文献10

二级参考文献17

  • 1Thomas Gbel,Sonja Vorderwülbecke,Katarzyna Hauck,Holger Fey,Dieter Hussinger,Andreas Erhardt.New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples[J].World Journal of Gastroenterology,2006,12(47):7604-7612. 被引量:21
  • 2Joachim Lupberger,Eberhard Hildt.Hepatitis B virus-induced oncogenesis[J].World Journal of Gastroenterology,2007,13(1):74-81. 被引量:57
  • 3Cassandra Willyard. Researchers look for ‘sweet' method to diagnose cancer. Nat Med, 2007, 13: 1267.
  • 4Kladney RD, Bulla GA, Guo L, et al. GP73, a novel golgilocalized protein upregulated by viral infection. Gene, 2000, 249 : 53-65.
  • 5Kladney RD, Cui X, Bulla GA, et al. Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease. Hepatology, 2002, 35 : 1431-1440.
  • 6Marrero JA, Romano PR, Nikolaeva O, et al. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol, 2005, 43: 1007-1012.
  • 7Prui S, Bachert C, Fimmel C J, et al. Cycling of early Golgi proteins via the cell surface and endosomes upon lumenal pH disruption [ J]. Traffic, 2002, 3(9): 641-653.
  • 8Kladney RD, Cui X, Bulla GA, et al. Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease [ J ]. Hepatology, 2002, 35(6) : 1431-1440.
  • 9Hu JS, Wu DW, Liang S, et al. GP73, a resident Golgi glycoprotein,is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population [ J]. Med Oncol, 2010, 27 (2) : 339-345.
  • 10Kladney RD, Tollefson AE, Wold WS, et al. Upregulation of the Golgi protein GP73 by adenovirus infection requires the E1A CtBP interaction domain [J]. Virology, 2002, 301(2): 236-246.

共引文献372

同被引文献59

  • 1吴明健(综述),李军锋(综述),周育森(审校).Glypican-3作为检测肝细胞癌新标志物的研究进展[J].中国卫生检验杂志,2007,17(10):1907-1909. 被引量:6
  • 2蔡永娥,乔建锦,孙晓茹,崔英.我国原发性肝癌研究进展[J].现代肿瘤医学,2008,16(1):141-143. 被引量:32
  • 3Dhanasekaran R, Limaye A, Cabrera R. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics[J]. Hepat Med, 2012, 4(6): 19-37.
  • 4Mao Y, Yang H, Xu H, et al. Golgi protein 73(GOLPH2) is a valuable serum marker for hepatocellular carcinoma[J]. Gut, 2010, 59(12):1687-1693.
  • 5Tian L, Wang Y, Xu D, et al. Serological AFP/golgi protein 73 could be a new diagnostic parameter of hepatic deseases[J]. Int J Cancer,2011, 129(8): 1923-1931.
  • 6Marrero JA, El-Serag HB .Alpha-fetoprot ein should be included in the hepatocellular carcinoma surveillance guidelines of the american association for the study of liver diseases[J] .Hepatology, 2011 ,53(3):1060.
  • 7毛一雷,杨华瑜,徐海峰. 肝细胞肝癌新的血清标记物GP73. 第十二届全国肝癌学术会议论文汇编, 2009: 52-53.
  • 8Yamamoto K, Imamura H , Matsuyama Y, et al.AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathologicalvariables of HCC[J] .Journal of Gastroenterology, 2010 , 45(12):1272-1282 .
  • 9Pilia G, Hughes-Benzie RM, Mackenzie A, et al. Mutalations in GPC3, a glyican genes cause the Simpeon-Golabi-Behmel overgrowth s-yndrome[J]. Nature Genet,1996,12:241-247.
  • 10Capurro MI, Xiang YY, Lobe C. Glypican3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling[J]. Cancer Research,2005,65:6245-6254.

引证文献4

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部